Verrica Pharmaceuticals Inc. (VRCA)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total revenue | 12,702 | 3,439 | -1,781 | |
| Cost of product revenue | 340 | 423 | 351 | |
| Cost of collaboration revenue | 154 | 14 | 84 | |
| Selling, general and administrative | 8,852 | 8,848 | 16,083 | |
| Research and development | 1,846 | 2,284 | 2,405 | |
| Total operating expenses | 11,192 | 11,569 | 18,923 | |
| Income (loss) from operations | 1,510 | -8,130 | -20,704 | |
| Other expense | -1 | - | -1 | |
| Interest income | 228 | 337 | 221 | |
| Interest expense | 2,131 | 2,203 | 2,376 | |
| Change in fair value of derivative liability | 598 | 254 | - | |
| Total other expense, net | -1,306 | -1,612 | -2,156 | |
| Net income (loss) | 204 | -9,742 | -22,860 | |
| Earnings per share, basic | 0.02 | -0.1 | -0.49 | |
| Earnings per share, diluted | 0.02 | -0.1 | -0.49 | |
| Weighted-average common shares outstanding, basic | 9,488,055 | 94,837,343 | 46,805,427 | |
| Weighted-average common shares outstanding, diluted | 9,490,600 | 94,837,343 | 46,805,427 | |